ATR and small cell lung carcinoma: A proof-of-concept phase II trial of the ATR inhibitor berzosertib in combination with topotecan in 25 relapsed SCLC patients reached its primary endpoint with an ORR of 36%, showing efficacy in patients with chemoresistant disease [79].